

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Inderjit Singh

Serial No.: 10/596,198

Filed: June 2, 2006


For: METHODS AND COMPOSITIONS FOR
THE PREVENTION AND TREATMENT
OF INFLAMMATORY DISEASES OR
CONDITIONS

Group Art Unit: 2622

Examiner: Unknown

Atty. Dkt. No.: MESC:013US

Confirmation No.: 3351

CERTIFICATE OF ELECTRONIC TRANSMISSION	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS Web on the date below.	
May 10, 2007	
Date	Michael R. Krawzsenek

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/MESC:013US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 10, 2007

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/MA/	A1	2001/0041726	11/15/01	Bandarage <i>et al.</i>	514	361	12/22/00
	A2	2003/0104348	06/05/03	Vodovotz <i>et al.</i>	435	1.2	08/28/02
	A3	2007/0027094	02/01/07	Singh	514	43	08/15/05
	A4	5,118,601	06/02/92	Gruber	435	5	08/31/89
	A5	5,130,333	07/14/92	Pan <i>et al.</i>	514	460	10/19/90
	A6	5,286,895	02/15/94	Harris <i>et al.</i>	560	60	12/07/92
	A7	5,498,536	03/12/96	Khandke	435	200	04/22/94
	A8	5,545,625	08/13/96	Gross <i>et al.</i>	514	33	12/12/94
	A9	5,658,889	08/19/97	Gruber <i>et al.</i>	514	43	12/14/94
	A10	5,695,761	12/09/97	Denhardt <i>et al.</i>	424	184.1	12/23/93
	A11	5,912,019	06/15/99	Singh	424	608	10/16/97
	A12	5,965,553	10/12/99	Bell <i>et al.</i>	514	211.09	06/12/97
	A13	5,968,983	10/19/99	Kaesemeyer	514	564	04/10/97
	A14	6,080,778	06/27/00	Yankner <i>et al.</i>	514	451	03/23/98
	A15	6,147,109	11/14/00	Liao <i>et al.</i>	514	460	08/11/98
	A16	6,204,248	03/20/01	Demopoulos <i>et al.</i>	514	21	12/09/99
	A17	6,312,662	11/06/01	Erion <i>et al.</i>	424	9.1	09/08/99
	A18	6,472,390	11/13/01	Stamler <i>et al.</i>	514	236.5	11/13/01
	A19	6,511,800	01/28/03	Singh	435	4	05/25/00
	A20	6,552,075	04/22/03	Gribble <i>et al.</i>	514	522	08/09/01
	A21	6,596,701	07/22/03	Schwartz <i>et al.</i>	514	46	03/16/98
	A22	6,605,729	08/12/03	Byrn <i>et al.</i>	548	537	06/28/02
/MA/	A23	6,649,629	11/18/03	Bandarage <i>et al.</i>	514	326	12/22/00

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)	Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Inderjit Singh	
	Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/MA/	A24	6,656,966	12/02/03	Garvey <i>et al.</i>	514	449	06/22/01
/MA/	A25	6,673,831	01/06/04	Tolbert	514	252.17	04/27/98
/MA/	A26	7,049,058	05/23/06	Singh	435	4	10/18/02

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
/MA/	B1	WO 93/14749	08/05/93	WIPO	English
/MA/	B2	WO 95/06470	03/09/95	WIPO	English
/MA/	B3	WO 98/09653	03/12/98	WIPO	French (English Abstract)

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C1	"Nymox pursuing new approaches to fighting Alzheimer's disease," <i>Business Wire</i> , July 2, 2004.
	C2	"Statins-the next miracle drug? Beyond cholesterol lowering," <i>Clinician Reviews</i> , 14(6):84(3), June 1, 2004.
	C3	Abud-Mendoza <i>et al.</i> , "Therapy with statins in patients with refractory rheumatic diseases: a preliminary study," <i>Lupus</i> , 12(8):607-611, 2003.
	C4	Akiyama <i>et al.</i> , "Cell mediators of inflammation in the Alzheimer disease brainm" <i>Alzheimer Dis. Assoc. Disord.</i> , 1:S47-53, 2000.
	C5	Akiyama <i>et al.</i> , "Inflammation and Alzheimer's disease," <i>Neurobiol. Aging</i> , 21:383-421, 2000.
	C6	Amerongen <i>et al.</i> , "Simvastatin improves disturbed endothelial barrier function," <i>Circulation</i> , 102:2803-2809, 2000.
/MA/	C7	Anderson <i>et al.</i> , "Astrocytes and stroke: networking for survival?," <i>Neurochem. Res.</i> , 28:293-305, 2003.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C8	Andoh <i>et al.</i> , "The role of neuronal nitric oxide synthase (NOS1) and related cyclic GMP-PKG signaling pathway on preconditioning-mediated neuroprotection," <i>Society for Neuroscience Abstracts</i> , 2001.
	C9	Appel <i>et al.</i> , "Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus," <i>Am. J. Cardiol.</i> , 76:29A-32A, 1995.
	C10	Arai <i>et al.</i> , "Lactosylceramide stimulates human neutrophils to upregulate Mac-1, adhere to endothelium, and generate reactive oxygen metabolites in vitro," <i>Circ. Res.</i> , 82:540-547, 1998.
	C11	Arbabi and Maier, "Mitogen-activated protein kinases," <i>Crit. Care Med.</i> , 30:S74-S79, 2002.
	C12	Azuma <i>et al.</i> , "HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation," <i>Cardiovascular Res.</i> , 64:412-420, 2004.
	C13	Bagasra <i>et al.</i> , "Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis," <i>Proc. Natl. Acad. Sci. USA</i> , 92:12041-12045, 1995.
	C14	Bal-Price and Brown, "Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity," <i>J. Neurosci.</i> , 21:6480-6491, 2001.
	C15	Barber <i>et al.</i> , "Biochemistry of Ischemic Stroke," <i>Adv. Neuro.</i> , 192:151-164, 2003.
	C16	Barone and Feuerstein, "Inflammatory mediators and stroke: new opportunities for novel therapeutics," <i>J. Cereb. Blood Flow Metab.</i> , 19:819-834, 1999.
	C17	Bauer <i>et al.</i> , "Inflammation in the Nervous System: The Human Perspective," <i>Glia</i> , 36:235-243, 2001.
	C18	Baughman, "Dopamine-transporter density in patients with ADHD," <i>The Lancet</i> , 355:1460-61, 2000.
	C19	Bedoya <i>et al.</i> , "Pyrrolidine dithiocarbamate prevents IL-1-induced nitric oxide synthase mRNA, but not superoxide dismutase mRNA, in insulin producing cells," <i>Biochemical and Biophysical Research Communications</i> , 210:816-822, 1995.
	C20	Bellosta <i>et al.</i> , "Direct vascular effects of HMG-CoA reductase inhibitors," <i>Atheroscl.</i> , 137:S101-109, 1998.
/MA/	C21	Bellosta <i>et al.</i> , "Non-lipid related effects of statins," <i>Ann. Med.</i> , 32:164-176, 2000.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C22	Benveniste <i>et al.</i> , "Cytokines: influence on glial cell gene expression and function," <i>Chem. Immunol.</i> , 69:31-75, 1997.
	C23	Berisha <i>et al.</i> , "Nitric oxide as a mediator of oxidant lung injury due to paraquat," <i>Proc. Natl. Acad. Sci. USA</i> , 91:7445-7449, 1994.
	C24	Berti <i>et al.</i> , "Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury," <i>J. Cereb. Blood Flow Metab.</i> , 22:1068-1079, 2002.
	C25	Bhunja <i>et al.</i> , "Lactosylceramide mediates tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 (ICAM-1) expression and the adhesion of neutrophil in human umbilical vein endothelial cells," <i>J. Biol. Chem.</i> , 273:34349-34357, 1998.
	C26	Bhunja <i>et al.</i> , "Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells," <i>J. Biol. Chem.</i> , 272:15642-15649, 1997.
	C27	Biesenbach and Zazgornik, "Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabetic nephropathy state IV-V," <i>Clin. Nephrology</i> , 37:274-279, 1992.
	C28	Blazquez <i>et al.</i> , "The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes," <i>FEBS Lett.</i> , 489:149-153, 2001.
	C29	Blight, "Anoxl Physiology of Chronic Spinal Cord Injury in the Cat: Intracellular Recording in Vitro," <i>Neuroscience</i> , 10:1471-1486, 1983.
	C30	Bo <i>et al.</i> , "Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains," <i>Ann. Neurol.</i> , 36:778-786, 1994.
	C31	Boese, "Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP," <i>Br. J Pharmacology</i> , 119:707-715, 1996.
	C32	Bolanos and Almeida, "Roles of nitric oxide in brain hypoxia-ischemia," <i>Biochem. Biophys. Acta</i> , 1411:415-436, 1999.
↓	C33	Boughton-Smith <i>et al.</i> , "Nitric oxide synthase activity in ulcerative colitis and Crohn's disease," <i>Lancet</i> , 342:338-340, 1993.
/MA/	C34	Bowen and Guyton, "Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol," <i>Current Science</i> , 2:58-63, 2000.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C35	Bredesen, "Neural apoptosis," <i>Ann. Neurol.</i> , 38:839-851, 1995.
	C36	Brugg <i>et al.</i> , "Ceramide induces apoptosis in cultured mesencephalic neurons," <i>J. Neurochem.</i> , 66:733-739, 1996.
	C37	Brune <i>et al.</i> , "Nitric oxide and its role in apoptosis," <i>Eur. J. Pharmacol.</i> , 351:261-272, 1998.
	C38	Buemi <i>et al.</i> , "Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy," <i>Clin. Phar. & Therapeutics</i> , 67:427-431, 2000.
	C39	Buisson <i>et al.</i> , "The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia," <i>Br. J. Pharmacol.</i> , 106:766-767, 1992.
	C40	Bull <i>et al.</i> , "Nitric Oxide Synthase in the Human Dermal Microvasculature," <i>J. Invest. Derm.</i> , 103:435, 1994 (Abstract No. 231).
	C41	Burney <i>et al.</i> , "The chemistry of DNA damage from nitric oxide and peroxynitrite," <i>Mutat. Res.</i> , 424:37-49, 1999.
	C42	Cartier <i>et al.</i> , "Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts," <i>Proc. Natl. Acad. Sci. USA</i> , 92:1674-1678, 1995.
	C43	Casey <i>et al.</i> , "p21ras is modified by a farnesyl isoprenoid," <i>Proc. Natl. Acad. Sci.</i> , 86:8323-27, 1989.
	C44	Catani <i>et al.</i> , "Inhibition of clotting factor XIII activity by nitric oxide," <i>Biochem. Biophys. Res. Commun.</i> , 249:275-278, 1998.
	C45	Cetkovic-Cvrlje <i>et al.</i> , "Nicotinamide and Dexamethasone Inhibit Interleukin-1-Induced Nitric Oxide Production by RINm5F Cells without Decreasing Messenger Ribonucleic Acid Expression for Nitric Oxide Synthase," <i>Endocrinology</i> , 133:1739-1743, 1993.
	C46	Chatterjee, "Sphingolipids in atherosclerosis and vascular biology," <i>Arterioscler. Thromb Vasc. Biol.</i> , 18:1523-1533, 1998.
	C47	Chen and Rosazza, "A bacterial nitric oxide synthase from a <i>Nocardia</i> species," <i>Biochem. Biophys. Res. Commun.</i> , 203:1251-1258, 1994.
/MA/	C48	Chieuh <i>et al.</i> , "S-nitrosoglutathione/nitric oxide system: A possible antioxidative cellular defense system in the brain," <i>Jpn. J. Pharmacol.</i> , pp. 8P, 1997 (Abstract No. 22).

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C49	Chiueh and Andoh, "Nitric oxide(cntdotNO) production through transfection and induction of NOS1 increases tolerance to 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity," <i>Society for Neuroscience Abstracts</i> , 2000.
	C50	Chiueh and Rauhala, "The redox pathway of S-nitrosoglutathione, glutathione and nitric oxide in cell to neuron communications," <i>Free Radic. Res.</i> , 31:641-650, 1999.
	C51	Chiueh <i>et al.</i> , "Enhanced Hydroxyl Radical Generation by 2'-Methyl Analog of MPTP: Suppression by Clorgyline and Deprenyl," <i>Synapse</i> , 11:346-348, 1992.
	C52	Chiueh, "Neuroprotective properties of nitric oxide," <i>Anns. NY Acad. Sci.</i> , 890:301-311, 1999 (Abstract Only).
	C53	Chiueh, "S-Nitrosoglutathione (GSNO) Mediates Brain Response to Hypoxia," <i>Pediatr. Res.</i> , 51:414, 2002.
	C54	Choi and Lipton, "Redox modulation of the NMDA receptor," <i>Cell Mol. Life Sci.</i> , 57:1535-1541, 2000.
	C55	Chung <i>et al.</i> , "Nitric oxide as a bioregulator of apoptosis," <i>Biochem. Biophys. Res. Commun.</i> , 282:1075-1079, 2001.
	C56	Coert <i>et al.</i> , "Effects of the nitric oxide donor 3-morpholinosydnonimine (SIN-1) in focal cerebral ischemia dependent on intracellular brain pH," <i>J. Neurosurg.</i> , 97:914-921, 2002.
	C57	Corbett and McDaniel, "Selective inhibition of inducible nitric oxide synthase by aminoguanidine," <i>Methods Enzymol.</i> , 268:398-408, 1996.
	C58	Corsini <i>et al.</i> , "Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors," <i>Cardiology</i> , 87:458-468, 1996.
	C59	Corton <i>et al.</i> , "5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?," <i>Eur. J. Biochem.</i> , 229:558-565, 1995.
	C60	Cross <i>et al.</i> , "Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice," <i>J. Clin. Invest.</i> , 93:2684-2690, 1994.
/MA/	C61	Cui <i>et al.</i> , "Oxidative DNA damage precedes DNA fragmentation after experimental stroke in rat brain," <i>Faseb J.</i> , 14:955-967, 2000.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)	Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Inderjit Singh	
	Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C62	Culmsee <i>et al.</i> , "AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation," <i>J. Mol. Neurosci.</i> , 17:45-58, 2001.
	C63	Cuzzocrea <i>et al.</i> , "Beneficial effects of n-acetylcysteine on ischemic brain injury," <i>British Journal of Pharmacology</i> , 130:1219-1226, 2000.
	C64	Davis <i>et al.</i> , "Novel effects of nitric oxide," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 41:203-236, 2001.
	C65	Davoli <i>et al.</i> , "Immunohistochemical and Biochemical Assessment of Caspase-3 Activation and DNA Fragmentation following Transient Focal Ischemia in the Rat," <i>Neuroscience</i> , 115:125-136, 2002.
	C66	Dawson <i>et al.</i> , "Nitric oxide as a mediator of neurotoxicity," <i>NIDA Res. Monogr.</i> , 136:258-271, 1993.
	C67	Devlin <i>et al.</i> , "Nitric oxide generation. A predictive parameter of acute allograft rejection," <i>Transplantation</i> , 58:592-595, 1994.
	C68	Dignam <i>et al.</i> , "Eukaryotic gene transcription with purified components," <i>Methods Enzymol.</i> , 101:582-598, 1983.
	C69	Ding-Zhou <i>et al.</i> , "L-NAME reduces infarction, neurological deficit and blood-brain brain disruption following cerebral ischemia in mice," <i>Eur. J. Pharmacol.</i> , 457:137-146, 2002.
	C70	Dirnagl <i>et al.</i> , "Pathobiology of ischaemic stroke: an integrated view," <i>Trends Neurosci.</i> , 22:391-397, 1999.
	C71	Dixon <i>et al.</i> , "AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent," <i>J. Clin. Pharmacol.</i> , 31:342-347, 1991.
	C72	Duval, "Effects of statins on ischemic stroke: neuroprotection and/or triggering of apoptotic damage?" Letters to the Editor, p. 989-990. Stroke. 2000 Apr; 31(4): 989-90.
	C73	Eisiek and Leijersfam, "The Inducible Form of Nitric Oxide Synthase (iNOS) in Insulin-Producing Cells," <i>Diabetes and Metabolism</i> , 20:116-122, 1994.
/MA/	C74	Evans <i>et al.</i> , "Differential effects of monoclonal antibodies to tumor necrosis factor alpha and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis," <i>Infect. Immun.</i> , 60:4133-4139, 1992.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C75	Faggioto and Paoletti, "Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action," <i>Hypertension</i> , 34:987-996, 1999.
	C76	Farmer, "Pleiotropic effects of statins," <i>Curr. Atheroscl. Rpts.</i> , 2:208-217, 2000.
	C77	Feigin <i>et al.</i> , "Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20 th century," <i>Lancet Neuro.</i> , 12:43-53, 2003.
	C78	Fenyk-Melody <i>et al.</i> , "Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the <i>NOS2</i> gene," <i>J. Immunol.</i> , 160:2940-2946, 1998.
	C79	Fern, "Ischemia: astrocytes show their sensitive side," <i>Prog. Brain Res.</i> , 132:405-411, 2001.
	C80	Ford <i>et al.</i> , "The reaction of superoxide radicals with S-nitrosoglutathione and the products of its reductive heterolysis," <i>J. Biol. Chem.</i> , 277:2430-2436, 2002.
	C81	Forster <i>et al.</i> , "Inducible nitric oxide synthase expression in human cerebral infarcts," <i>Acta Neuropathol.</i> , 97:215-220, 1999.
	C82	Fortenberry <i>et al.</i> , "S-nitrosoglutathione inhibits TNF-alpha-induced NFkappaB activation in neutrophils," <i>Inflamm Res.</i> , 50:89-95, 2001.
	C83	Foster <i>et al.</i> , "S-nitrosylation in health and disease," <i>Trends Mol. Med.</i> , 9:160-168, 2003.
	C84	Frances <i>et al.</i> , "Outcome of kidney transplant recipients with previous human herpesvirus-8 infection," <i>Transplantation</i> , 69:1776-1779, 2000.
	C85	Fukuo <i>et al.</i> , "Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/macrophages," <i>J. Nippon Med. Sch.</i> , 62:74-78, 1995.
	C86	Fukuzawa <i>et al.</i> , "N-acetylcysteine ameliorates reperfusion injury after warm hepatic ischemia," <i>Transplantation</i> , 59(1):6-9, 1995.
	C87	Galinanes <i>et al.</i> , "Sustained protection by acadesine against ischemia- and reperfusion-induced injury: Studies in the transplanted rat heart," <i>Circulation</i> , 86(2):589-611, 1992.
	C88	Garg, "Treatment of diabetic dyslipidemia," <i>Am. J. Cardiol.</i> , 81:47B-51B, 1998.
	C89	Geibicke-Haerter, "Microglia in neurodegeneration: molecular aspects," <i>Microsc. Res. Tech.</i> , 54:47-58, 2001.
/MA/	C90	Ghosh and Karin, "Missing pieces in the NF-kappaB puzzle," <i>Cell</i> , 109:S81-S96, 2002.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C91	Gilg <i>et al.</i> , "Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy," <i>J. Neuropathol. Exp. Neurol.</i> , 59:1063-1069, 2000.
	C92	Ginsberg and Busto, "Rodent models of cerebral ischemia," <i>Stroke</i> , 20:1627-1642, 1989.
	C93	Giri <i>et al.</i> , "5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase," <i>J. Neuroscience</i> , 24(2):479-487, 2004.
	C94	Giri <i>et al.</i> , "Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease," <i>FASEB J.</i> , 16:661-672, 2002.
	C95	Giustizieri <i>et al.</i> , "Nitric Oxide Donors Suppress Chemokine Production by Keratinocytes in Vitro and in Vivo," <i>Am. J. Pathol.</i> , 1161:1409-1418.; 2002 Oct.
	C96	Gmerek <i>et al.</i> , "A 4-Year, Placebo-Controlled Study of Atorvastatin as Prevention of CHD Endpoints in Patients with Non-Insulin Dependent Diabetes Melitus," <i>Abstract Book, 57th Annual Meeting and Scientific Sessions</i> , 363A, 1997.
	C97	Goalstone and Draznin, "Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes," <i>J. Biol. Chem.</i> , 271:27585-27589, 1996.
	C98	Goldberg <i>et al.</i> , "Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial," <i>Circulation</i> , 98:2513-2519, 1998.
	C99	Goureau <i>et al.</i> , "Lipopolysaccharide and cytokines induce a macrophage-type of nitric oxide synthase in bovine retinal pigmented epithelial cells," <i>Biochem. Biophys. Res. Commun.</i> , 186:854-859, 1992.
	C100	Green and Chabrier, "Nitric oxide: from basic research to clinical applications," <i>Drug Discov. Today</i> , 4:47-49, 1999.
	C101	Green <i>et al.</i> , "Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids," <i>Anal. Biochem.</i> , 126:131-138, 1982.
/MA/	C102	Griffith and Kilbourn, "Design of Nitric Oxide Synthase Inhibitors and Their Use to Reverse Hypertension Associated with Cancer Immunotherapy," <i>Advan. Enzyme Regul.</i> , 37:171-194, 1997.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C103	Grip <i>et al.</i> , "Pravastatin down-regulates inflammatory mediators in human monocytes in vitro," <i>Eur. J. Pharmacol.</i> , 410:83-92, 2000.
	C104	Gruner, "A monitored contusion model of spinal cord injury in the rat," <i>J. Neurotrauma</i> , 9:123-126, 1992.
	C105	Gu <i>et al.</i> , "S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death," <i>Science</i> , 297:1186-1190, 2002.
	C106	Haga <i>et al.</i> , "Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells," <i>Brain Res.</i> , 601:88-94, 1993.
	C107	Hakomori and Handa, "Interaction of glycosphingolipids with signal transducers and membrane proteins in glycosphingolipid-enriched microdomains," <i>Methods Enzymol.</i> , 363:191-207, 2003.
	C108	Hallenbeck, "The many faces of tumor necrosis factor in stroke," <i>Nat. Med.</i> , 8:1363-1368, 2002.
	C109	Hamid <i>et al.</i> , "Induction of nitric oxide synthase in asthma," <i>Lancet</i> , 342:1510-1513, 1993.
	C110	Han <i>et al.</i> , "Mild Hypothermia Inhibits Nuclear Factor-kappaB Translocation in Experimental Stroke," <i>J. Cereb. Blood Flow Metab.</i> , 23:589-598, 2002.
	C111	Hannun, "The sphingomyelin cycle and the second messenger function of ceramide," <i>J. Biol. Chem.</i> , 269:3125-3128, 1994.
	C112	Haq <i>et al.</i> , "Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line," <i>J. Neurochem.</i> , 86:1428-1440, 2003.
	C113	Hardie and Carling, "The AMP-activated protein kinase--fuel gauge of the mammalian cell?," <i>Eur. J. Biochem.</i> , 246:259-273, 1997.
	C114	Hardie <i>et al.</i> , "The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?," <i>Annu. Rev. Biochem.</i> , 67:821-855, 1998.
	C115	Hardie, "Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase," <i>Biochem. Biophys. Acta</i> , 1123:231-238, 1992.
/MA/	C116	Hardy <i>et al.</i> , "Effect of exogenous fatty acids with greater than 22 carbon atoms (very long chain fatty acids) on superoxide production by human neutrophils," <i>J. Immunol.</i> , 153:1754-1761, 1994.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C117	Hashimoto <i>et al.</i> , "5-amino-4-imidazolecarboxamide riboside confers strong tolerance to glucose starvation in a 5'-AMP-activated protein kinase-dependent fashion," <i>Biochemical and Biophysical Research Communications</i> , 290:263-267, 2002.
	C118	Hashmi <i>et al.</i> , "Lignoceroyl-CoASH ligase: enzyme defect in fatty acid beta-oxidation system in X-linked childhood adrenoleukodystrophy," <i>FEBS Lett.</i> , 196:247-250, 1986.
	C119	Hawley <i>et al.</i> , "Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase," <i>J. Biol. Chem.</i> , 271:27879-27887, 1996.
	C120	Hays, "Therapeutic approaches to the treatment of neuroinflammatory diseases," <i>Curr. Pharm. Des.</i> , 4:335-348, 1998.
	C121	Herrmann <i>et al.</i> , "Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase," <i>J. Biol. Chem.</i> , 270:2901-2905, 1995.
	C122	Hesse <i>et al.</i> , "Cytokine appearance in human endotoxemia and primate bacteremia," <i>Surg. Gynecol. Obstet.</i> , 166:147-153, 1988.
	C123	Hibbs <i>et al.</i> , "Evidence for cytokine-inducible nitric oxide synthesis from l-arginine in patients receiving interleukin-2 therapy," <i>J. Clin. Invest.</i> , 89:867-877, 1992.
	C124	Hirasawa <i>et al.</i> , "Possible role of macrophage-derived soluble mediators in the pathogenesis of encephalomyocarditis virus-induced diabetes in mice," <i>J. Virol.</i> , 71:4024-4031, 1997.
	C125	Hogg, "Biological chemistry and clinical potential of S-nitrosothiols," <i>Free Radic. Biol. Med.</i> , 28:1478-1486, 2000.
	C126	Hogg, "The biochemistry and physiology of S-nitrosothiols," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 42:585-600, 2002.
	C127	Hohmeier <i>et al.</i> , "Stable expression of manganese superoxide dismutase (MnSOD) in insulinoma cells prevents IL-1 beta- induced cytotoxicity and reduces nitric oxide production," <i>J. Clin. Invest.</i> , 101:1811-1820, 1998.
/MA/	C128	Hooper <i>et al.</i> , "Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis," <i>Proc. Natl. Acad. Sci. USA</i> , 94:2528-2533, 1997.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C129	Hooper <i>et al.</i> , "Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis," <i>Proc. Natl. Acad. Sci. USA</i> , 95:675-680, 1998.
	C130	Horwich <i>et al.</i> , "Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure," <i>J. Am. College of Cardiol.</i> , 43(4):642-548, 2004.
	C131	Hu <i>et al.</i> , "The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1," <i>J. Biol. Chem.</i> , 275:16373-16381, 2000.
	C132	Huang <i>et al.</i> , "Effects of Cerebral Ischemia in Mice Deficient in Neuronal Nitric Oxide Synthase," <i>Science</i> , 265:1883-1885, 1994.
	C133	Huang <i>et al.</i> , "Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine," <i>J. Cereb. Blood Flow Metab.</i> , 16:981-987, 1996.
	C134	Iadecola <i>et al.</i> , "Inducible nitric oxide synthase gene expression in brain following cerebral ischemia," <i>J. Cereb. Blood Flow Metab.</i> , 15:378-384, 1995.
	C135	Iadecola, "Bright and dark sides of nitric oxide in ischemic brain injury," <i>Trends Neurosci.</i> , 20:132-139, 1997.
	C136	Iimura <i>et al.</i> , "HMG-CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture," <i>Kidney International</i> , 52:962-972, 1997.
	C137	Ikeda and Shumada, "Statins and monocytes," <i>The Lancet</i> , 353:2070, 1999.
	C138	Inoue <i>et al.</i> , "Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect reduction of mRNA levels for interleukin-1 β , interleukin-6, cyclooxygenase-2 and p22phox by regulation of peroxisome proliferator-activated receptor α (PPAR α) in preimary endothelial cells," <i>Life Sciences</i> , 67:863-876, 2000.
	C139	Issazadeh <i>et al.</i> , "Interferon γ , interleukin 4 and transforming growth factor β in experimental autoimmune encephalomyelitis in lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells," <i>J. Neuroscience. Res.</i> , 40:579-590, 1995.
	C140	Iwabuchi and Nagaoka, "Lactosylceramide-enriched glycosphingolipid signaling domain mediates superoxide generation from human neutrophils," <i>Blood</i> , 100:1454-1464, 2002.
/MA/	C141	Izzat <i>et al.</i> , "New molecular targets for cholesterol-lowering therapy," <i>J. Pharmacol. & Exp. Therapeutics</i> , 293:315-320, 2000.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C142	Janero, "Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation," <i>Free Radic. Biol. Med.</i> , 28:1495-1506, 2000.
	C143	Johnson <i>et al.</i> , "Endothelial damage due to ischemia and reperfusion is prevented with SIN-1," <i>Cardiovasc. Surg.</i> , 6:367-372, 1998.
	C144	Johnson, "Multi-Purpose Medicine," http://my.abcnews.go.com 2000
	C145	Jord'heui <i>et al.</i> , "Oxidation and nitrosation of thiols at low micromolar exposure to nitric oxide. Evidence for a free radical mechanism," <i>J. Biol. Chem.</i> , 278:15720-15726, 2003.
	C146	Josefsen, "Statins may reduce risk of Alzheimer's disease," <i>BMJ</i> , 321:28, 2000.
	C147	Joshi <i>et al.</i> , "Effect of Aminogluanidine on in Vivo Expression of Cytokines and Inducible Nitric Oxide Synthase in the Lungs of Endotoxemic Rats," <i>Res. Commun. Mol. Pathol. Pharmacol. Mar.</i> , 91:339-346, 1996.
	C148	Jukema <i>et al.</i> , "Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels," <i>Circulation</i> , 91:2528-2540, 1995.
	C149	Jungnickel <i>et al.</i> , "Pravastatin: a new drug for the treatment of hypercholesterolemia," <i>Clin. Pharm.</i> , 11:677-689, 1992.
	C150	Kametsu <i>et al.</i> , "Apoptosis occurs in the penumbra zone during short-duration focal ischemia in the rat," <i>J. Cereb. Blood Flow Metab.</i> , 23:416-422, 2003.
	C151	Kanety <i>et al.</i> , "Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1," <i>J. Biol. Chem.</i> , 270:23780-23784, 1995.
	C152	Kaposzta <i>et al.</i> , "S-Nitrosoglutathione Reduces Asymptomatic Embolization After Carotid Angioplasty," <i>Circulation</i> , 106:3057-3062, 2002.
	C153	Kaposzta <i>et al.</i> , "Switching off Embolization From Symptomatic Carotid Plaque Using S-Nitrosoglutathione," <i>Circulation</i> , 105:1480-1484, 2002.
	C154	Kato <i>et al.</i> , "Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat," <i>Brain Res.</i> , 734:203-212, 1996.
/MA/	C155	Katznelson <i>et al.</i> , "The effect of pravastatin on acute rejection after kidney transplantation - a pilot study," <i>Transplantation</i> , 61:1469-1474, 1996.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C156	Kaur and Halliwell, "Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients," <i>FEBS Lett.</i> , 350:9-12, 1994.
	C157	Keinanen <i>et al.</i> , "Molecular cloning and characterization of the rat inducible nitric oxide synthase (iNOS) gene," <i>Gene</i> , 234:297-305, 1999.
	C158	Kemp <i>et al.</i> , "Dealing with energy demand: the AMP-activated protein kinase," <i>Trends Biochem. Sci.</i> , 24:22-25, 1999.
	C159	Khan <i>et al.</i> , "Cytokine-induced accumulation of very long-chain fatty acids in rat C6 glial cells: implication for X-adrenoleukodystrophy," <i>J. Neurochem.</i> , 71:78-87, 1998.
	C160	Khan <i>et al.</i> , "Endotoxin-induced alterations of lipid and fatty acid compositions in rat liver peroxisomes," <i>J. Endotoxin Res.</i> , 6:41-50, 2000.
	C161	Khan <i>et al.</i> , "S-nitrosoglutathione modulates cerebroprotectin and activities of sphingomyelinases and phospholipases in a rat model of experimental stroke," <i>J. Cereb. Blood Flow Metab.</i> , 25:177-192, 2005.
	C162	Kharitonov <i>et al.</i> , "Increased nitric oxide in exhaled air of asthmatic patients," <i>Lancet</i> , 343:133-135, 1994.
	C163	Kiernan, "Interactions between mast cells and nerves. Neurogenic inflammation," <i>Trends Pharmacol. Sci.</i> , 11:316, 1990.
	C164	Kim <i>et al.</i> , "Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway," <i>J. Biol. Chem.</i> , 276:19102-19110, 2001.
	C165	Kim <i>et al.</i> , "JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain microglial cells," <i>J. Biol. Chem.</i> , 277:40594-40601, 2002.
	C166	Kim <i>et al.</i> , "Nitric oxide as a bifunctional regulator of apoptosis," <i>Circ. Res.</i> , 84:253-256, 1999.
↓	C167	Kim <i>et al.</i> , "The regulatory role of nitric oxide in apoptosis," <i>Int. Immunopharmacol.</i> , 1:1421-1441, 2001.
/MA/	C168	Kjaer <i>et al.</i> , "Effect of simvastatin in patients with type I (insulin-dependent) diabetes mellitus and hypercholesterolemia," <i>Acta Endocrin.</i> , 126:229-232, 1992.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C169	Klinkert <i>et al.</i> , "TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview," <i>J. Neuroimmunol.</i> , 72:163-168, 1998.
	C170	Kluge <i>et al.</i> , "S-nitrosoglutathione in rat cerebellum: Identification and quantification by liquid chromatography: Mass spectrometry," <i>J. Neurochem.</i> , 69:2599-2607, 1997.
	C171	Knuckey <i>et al.</i> , "N-acetylcysteine enhances hippocampal neuronal survival after transient forebrain ischemia in rats," <i>Stroke</i> , 26:305-311, 1995.
	C172	Kolb-Bachofen <i>et al.</i> , "Epidermal keratinocyte expression of inducible nitric oxide synthase in skin lesions of psoriasis vulgaris," <i>Lancet</i> , 344:139, 1994.
	C173	Kolesnick <i>et al.</i> , "The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation," <i>Biochem. Cell Biol.</i> , 72:471-474, 1994.
	C174	Koprowski <i>et al.</i> , "In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3024-3027, 1993.
	C175	Kothe <i>et al.</i> , "Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae," <i>Circulation</i> , 101:1760-1763, 2000.
	C176	Kroncke <i>et al.</i> , "Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation," <i>Biochem. Biophys. Res. Commun.</i> , 175:752-758, 1991.
	C177	Kurakata <i>et al.</i> , "Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HGM-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro," <i>Immunopharmacology</i> , 34:51-61, 1996.
	C178	Kwak <i>et al.</i> , "Statins as a newly recognized type of immunomodulator," <i>Nat. Med.</i> , 6:1399-1402, 2000.
	C179	Langford <i>et al.</i> , "Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty," <i>Lancet</i> , 344:1458-1460, 1994.
/MA/	C180	Lassmann and Wisniewski, "Chronic relapsing experimental allergic encephalomyelitis: clinicopathological comparison with multiple sclerosis," <i>Arch. Neurol.</i> , 36:490-497, 1979.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)	Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Inderjit Singh	
	Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C181	Lazo <i>et al.</i> , "Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy," <i>Proc. Natl. Acad. Sci. USA</i> , 85:7647-7651, 1988.
	C182	Lee <i>et al.</i> , "Nitric oxide mediates Fos expression in the spinal cord induced by mechanical noxious stimulation," <i>NeuroReport</i> , 3:841-844, 1992.
	C183	Leist <i>et al.</i> , "Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity," <i>Eur. J. Neurosci.</i> , 9:1488-1498, 1997.
	C184	Leker and Shohami, "Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities," <i>Brain Res. Brain Res Rev.</i> , 39:55-73, 2002.
	C185	Leung <i>et al.</i> , "A novel anti-inflammatory role for simvastatin in inflammatory arthritis," <i>J. Immunol.</i> , 170:1524-1530, 2003.
	C186	Li and Forstermann, "Nitric oxide in the pathogenesis of vascular disease," <i>J. Pathol.</i> , 190:244-254, 2000.
	C187	Linardic <i>et al.</i> , "Activation of the sphingomyelin cycle by brefeldin A: effects of brefeldin A on differentiation and implications for a role for ceramide in regulation of protein trafficking," <i>Cell Growth Differ.</i> , 7:765-774, 1996.
	C188	Lipton <i>et al.</i> , "Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation," <i>Trends Neurosci.</i> , 25:474-480, 2002.
	C189	Lipton <i>et al.</i> , "S-Nitrosothiols signal the ventilatory response to hypoxia," <i>Nature</i> , 413:171-174, 2001.
	C190	Lipton, "Nitric oxide and respiration," <i>Nature</i> , 413:118-121, 2001.
	C191	Liu <i>et al.</i> , "Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells," <i>J. Biol. Chem.</i> , 274:1140-1146, 1999.
	C192	Liu <i>et al.</i> , "Ischemic injury and faulty gene transcripts in the brain," <i>Trends Neurosci.</i> , 24:581-588, 2001.
/MA/	C193	Liu <i>et al.</i> , "Neuronal and glial apoptosis after traumatic spinal cord injury," <i>J. Neurosci.</i> , 17:5395-5406, 1997.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C194	Love, "Apoptosis and brain ischaemia," <i>Neuro-Psychopharmacol. Biol. Psychiatry</i> , 27:267-282, 2003.
	C195	Lowick <i>et al.</i> , "Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption," <i>J. Clin. Invest.</i> , 93:1465-1472, 1994.
	C196	Maggard <i>et al.</i> , "Effects of pravastatin on chronic rejection of rat cardiac allografts," <i>Transplantation</i> , 65:149-155, 1998.
	C197	Maimone <i>et al.</i> , "Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis," <i>J. Neuroimmunol.</i> , 32:67-74, 1991.
	C198	Mandai <i>et al.</i> , "The Role of Nitric Oxide Synthase in Endotoxin-Induced Uveitis: Effects of NG-Nitro L-Arginine," <i>Invest. Ophthalmol.</i> , 35:3673-3680, 1994.
	C199	Mannick <i>et al.</i> , "Fas-Induced Caspase Denitrosylation," <i>Science</i> , 284: 651-654, 1999.
	C200	Mannick <i>et al.</i> , "S-Nitrosylation of mitochondrial caspases," <i>J. Cell Biol.</i> , 154:1111-1116, 2001.
	C201	Marcus <i>et al.</i> , "Cytokine-stimulated inducible nitric oxide synthase expression in astroglia: role of Erk mitogen-activated protein kinase and NF-kappaB," <i>Glia</i> , 41:152-160, 2003.
	C202	Maron <i>et al.</i> , "Current perspectives on statins," <i>Circulation</i> , 101:207-213, 2000.
	C203	Marshall and Stamler, "Inhibition of NF-kappaB by S-Nitrosylation," <i>Biochemistry</i> , 40:1688-1693, 2001.
	C204	Marshall and Stamler, "Nitrosative stress-induced apoptosis through inhibition of NF-kappa B," <i>J. Biol. Chem.</i> , 277:34223-34228, 2002.
	C205	Marz and Wieland, "HMG-CoA reductase inhibition - anti-inflammatory effects beyond lipid lowering?" <i>Herz</i> , 25:117-125, 2000.
	C206	Matsuyama <i>et al.</i> , "Nitric oxide: a possible etiologic factor in spinal cord cavitation," <i>J. Spinal Disord.</i> , 11:248-252, 1998.
/MA/	C207	Mattson and Camandola, "NF-kappaB in neuronal plasticity and neurodegenerative disorders," <i>J. Clin. Invest.</i> , 107:247-254, 2001.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C208	McCarthy and de Vellis, "Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue," <i>J. Cell Biol.</i> , 85:890-902, 1980.
	C209	McCartney-Francis <i>et al.</i> , "Suppression of arthritis by an inhibitor of nitric oxide synthase," <i>J. Exp. Med.</i> , 178:749-754, 1993.
	C210	McCarty, "Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation," <i>Medical Hypotheses</i> , 56:12-17, 2001.
	C211	McDaniel <i>et al.</i> , "Cytokines and nitric oxide in islet inflammation and diabetes," <i>Proc. Soc. Exp. Biol. Med.</i> , 211:24-32, 1996.
	C212	McGuiness <i>et al.</i> , "Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinating lesions of X-linked adrenoleukodystrophy and multiple sclerosis," <i>J. Neuroimmunol.</i> , 75:174-182, 1997.
	C213	McGuiness <i>et al.</i> , "Tumor necrosis factor-alpha and X-linked adrenoleukodystrophy," <i>J. Neuroimmunol.</i> , 61:161-169, 1995.
	C214	Megson, "Nitric oxide donor drugs," <i>Drugs of the Future</i> , 25:701-715, 2000.
	C215	Meller <i>et al.</i> , "Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-D-aspartate-produced facilitation of the nociceptive tail-flick reflex," <i>Eur. J. Pharmacol.</i> , 214:93-96, 1992.
	C216	Menasche <i>et al.</i> , "Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting," <i>Journal of Thoracic and Cardiovascular Surgery</i> , 110(4):1096-1106, 1995.
	C217	Merrill and Benveniste, "Cytokines in inflammatory brain lesions: helpful and harmful," <i>Trends Neurosci.</i> , 19:331-338, 1996.
	C218	Merrill <i>et al.</i> , "Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide," <i>J. Immunol.</i> , 151:2132-2141, 1993.
	C219	Middleton <i>et al.</i> , "Increased nitric oxide synthesis in ulcerative colitis," <i>Lancet</i> , 34:465-466, 1993.
/MA/	C220	Miller and Chacko, "The role of cholesterol and statins in Alzheimer's Disease," <i>Annals of Pharmacotherapy</i> , 38:91-98, 2004.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C221	Miller <i>et al.</i> , "Amelioration of chronic ileitis by nitric oxide synthase inhibition," <i>J. Pharmacol. & Exp. Therapeutics</i> , 264:11-16, 1992.
	C222	Mitrovic <i>et al.</i> , "Nitric Oxide as a Potential Pathological Mechanism in Demyelination: Its Differential Effects on Primary Glial Cells in Vitro," <i>Neurosci.</i> , 61:575-585, 1994.
	C223	Mohr <i>et al.</i> , "Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide," <i>Biochem. Biophys. Res. Commun.</i> , 238:387-391, 1997.
	C224	Molloy <i>et al.</i> , "S-Nitrosoglutathione Reduces the Rate of Embolization in Humans," <i>Circulation</i> , 98:1372-1375, 1998.
	C225	Moore <i>et al.</i> , "7-Nitro indazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure," <i>Br. J. Pharmacol.</i> , 108:296-297, 1992.
	C226	Moore <i>et al.</i> , "Evidence that AMP triggers phosphorylation as well as direct allosteric activation of rat liver AMP-activated protein kinase. A sensitive mechanism to protect the cell against ATP depletion," <i>Eur. J. Biochem.</i> , 199:691-697, 1991.
	C227	Moore <i>et al.</i> , "L-NG-bito arginine methyl ester exhibits antinociceptive activity in the mouse," <i>Br. J. Pharmacol.</i> , 102:198-202, 1991.
	C228	Moser <i>et al.</i> , "Adrenoleukodystrophy: Survey of 303 Cases: Biochemistry, Diagnosis, and Therapy," <i>Ann. Nerol.</i> , 16:628-641, 1984.
	C229	Moser <i>et al.</i> , "Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters," <i>Nature</i> , 361:726-730, 1993.
	C230	Moser, "Clinical and Therapeutic Aspects of Adrenoleukodystrophy and Adrenomyeloneuropathy," <i>J. Neuropathol. Expt. Neurol.</i> , 54:740-744, 1995.
	C231	Muhl <i>et al.</i> , "Expression of nitric oxide synthase in rat glomerular mesangial cells mediated by cyclic AMP," <i>Br. J. Pharmacol.</i> , 112:1-8, 1994.
↓	C232	Mulligan <i>et al.</i> , "Protective effects of inhibitors of nitric oxide synthase in immune complex-induced vasculitis," <i>Br. J. Pharmacol.</i> , 107:1159-1162, 1992.
/MA/	C233	Nagafuji <i>et al.</i> , "Blockade of nitric oxide formation by N omega-nitro-L-arginine mitigates ischemic brain edema and subsequent cerebral infarction in rats," <i>Neurosci.</i> , 147:159-162, 1992.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C234	Namura <i>et al.</i> , "Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia," <i>J. Neurosci.</i> , 18:3659-3668, 1998.
	C235	Napoli, "HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention," <i>Neurology</i> , 55:1066-1070, 2000.
	C236	Nunokawa <i>et al.</i> , "Human inducible nitric oxide synthase gene is transcriptionally regulated by nuclear factor-kappaB dependent mechanism," <i>Biochem. Biophys. Res. Commun.</i> , 223:347-352, 1996.
	C237	Oda and Keane, "Recent advances in statins and the kidney," <i>Kidney Intl.</i> , 56:S-2-S-5, 1999.
	C238	Olesen <i>et al.</i> , "Nitric oxide is a key molecule in migraine and other vascular headaches," <i>Trends Pharmacol. Sci.</i> , 15:149-153, 1994.
	C239	Ongini <i>et al.</i> , "Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties," <i>Proc. Natl. Acad. Sci., USA</i> , 101(22):8497-8502, 2004.
	C240	Ortego <i>et al.</i> , "Atorvastatin reduces NF-κK activation and chemokine expression in vascular smooth muscle cells and mononuclear cells," <i>Atherosclerosis</i> , 147:253-261, 1999.
	C241	Page <i>et al.</i> , "Treatment of Lesch-Nyhan syndrome with AICAR," <i>Adv. Exp. Med. Biol.</i> , 370:353-356, 1994.
	C242	Pahan <i>et al.</i> , "Expression of a dominant-negative mutant of p21(ras) inhibits induction of nitric oxide synthase and activation of nuclear factor-kappaB in primary astrocytes," <i>J. Neurochem.</i> , 74:2288-2295, 2000.
	C243	Pahan <i>et al.</i> , "Increasing cAMP Attenuates Induction of Inducible Nitric-oxide Synthase in Rat Primary Astrocytes," <i>J. Biological Chemistry</i> , 272:7786-7791, 1997.
	C244	Pahan <i>et al.</i> , "Induction of the manganese superoxide dismutase gene by sphingomyelinase and ceramide," <i>J. Neurochem.</i> , 73:513-520, 1999.
	C245	Pahan <i>et al.</i> , "Lovastatin and phenylacetate inhibit the induction of NOS and cytokines in rat primary astrocytes, microglia and macrophages," <i>J. Clinical Invest</i> , 100:2671-2679, 1997.
/MA/	C246	Pahan <i>et al.</i> , "Sphingomyelinase and ceramide stimulate the expression of inducible nitric-oxide synthase in rat primary astrocytes," <i>J. Biol. Chem.</i> , 273:2591-2600, 1998.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C247	Parving, "Cholesterol-lowering therapy may retard the progression of diabetic nephropathy," <i>Diabetologia</i> , 39:367-373, 1996.
	C248	Paul <i>et al.</i> , "Differential regulation by protein kinase C isoforms of nitric oxide synthase induction in RAW 264.7 macrophages and rat aortic smooth muscle cells," <i>British J of Pharmacology</i> , 120:940-946, 1997.
	C249	PCT International Search Report and Written Opinion, dated May 18, 2005.
	C250	Petros <i>et al.</i> , "Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock," <i>Lancet</i> , 338:1557-1558, 1991.
	C251	Pitossi <i>et al.</i> , "Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice," <i>J. Neurosci. Res.</i> , 48:287-298, 1997.
	C252	Poli, "The role of C/EBP isoforms in the control of inflammatory and native immunity functions," <i>J. Biol. Chem.</i> , 273:29279-29282, 1998.
	C253	Powers <i>et al.</i> , "The Inflammatory Myelinopathy of Adreno-Leukodystrophy: Cells, Effector Molecules, and Pathogenetic Implications," <i>J. Neuropathol. Expt. Neurol.</i> , 51:630-643, 1992.
	C254	Powers, "The Pathology of Peroxisomal Disorders with Pathogenetic Considerations," <i>J. Neuropathol. Expt. Neurol.</i> , 54:710-719, 1995.
	C255	Rauhala and Chiueh, "Effects of atypical antioxidative agents, S-nitrosoglutathione and manganese, on brain lipid peroxidation induced by iron leaking from tissue disruption," In: <i>Annals of the New York Academy of Sciences; Reactive oxygen species: From radiation to molecular biology</i> , Chieuh (ed.), pp. 238-254, 2000.
	C256	Rauhala <i>et al.</i> , "Neuroprotection by S-nitrosoglutathione of brain dopamine neurons from oxidative stress," <i>FASEB J.</i> , 12:165-173, 1998.
	C257	<i>Remington's Pharmaceutical Sciences</i> , 18 TH Ed. Mack Printing Company, 1990.
	C258	Richardson and Benjamin, "Potential therapeutic uses for S-nitrosothiols," <i>Clinical Science</i> , 102:99-105, 2002.
	C259	Rizzo <i>et al.</i> , "Adrenoleukodystrophy: Oleic acid lowers fibroblast saturated C22-26 fatty acids," <i>Neurology</i> , 36:357-361, 1986.
/MA/	C260	Rizzo <i>et al.</i> , "Dietary erucic acid therapy for X-linked adrenoleukodystrophy," <i>Neurology</i> , 39:1415-1422, 1989.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C261	Rodriguez <i>et al.</i> , "Chemical nature of nitric oxide storage forms in rat vascular tissue," <i>Proc. Natl. Acad. Sci. USA</i> , 100:336-341, 2003.
	C262	Rogers <i>et al.</i> , "Complement activation by beta-amyloid in Alzheimer disease," <i>Proc. Natl. Acad. Sci. USA</i> , 89:10016-10020, 1992.
	C263	Romano <i>et al.</i> , "Inhibition of monocyte chemotactic protein-1 synthesis by statins," <i>Lab. Investigation</i> , 80:1095-1100, 2000.
	C264	Rothwell, "Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential," <i>Brain Behav. Immun.</i> , 17:152-157, 2003.
	C265	Rudick and Ransohoff, "Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity," <i>Arch. Neurol.</i> , 49:265-270, 1992.
	C266	Ruuls <i>et al.</i> , "Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors," <i>Clin. Exp. Immunol.</i> , 103:467-474, 1996.
	C267	Ruzicka <i>et al.</i> , "Inducible Nitric Oxide Synthase (iNOS) in Skin: Marked Expression in Psoriatic Epidermis," <i>J. Invest. Derm.</i> , 103:397, 1994.
	C268	Sacks <i>et al.</i> , "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels," <i>New Engl. J. Med.</i> , 335(14):1001-1009, 1996.
	C269	Saliba and Henrot, "Inflammatory mediators and neonatal brain damage," <i>Biol. Neonate.</i> , 79:224-227, 2001.
	C270	Salom <i>et al.</i> , "Reduction of infarct size by the NO donors sodium nitroprusside and spermine/NO after transient focal cerebral ischemia in rats," <i>Brain Res.</i> , 865:149-156, 2000.
	C271	Salt <i>et al.</i> , "AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform," <i>Biochem. J.</i> , 334:177-187, 1998.
	C272	Sambrook <i>et al.</i> , In: Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 2001.
	C273	Sarti <i>et al.</i> , "International trends in mortality from stroke, 1968 to 1994," <i>Stroke</i> , 31:1588-1601, 2000.
/MA/	C274	Satake <i>et al.</i> , "Nitric oxide via macrophage iNOS induces apoptosis following traumatic spinal cord injury," <i>Brain Res. Mol. Brain Res.</i> , 85:114-122, 2000.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C275	Schilling <i>et al.</i> , "A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetase," <i>Intensive Care Med.</i> , 19:227-231, 1993.
	C276	Schrammel <i>et al.</i> , "S-nitrosation of glutathione by nitric oxide, peroxynitrite, and (*)NO/O(2)(*-)," <i>Free Radic. Biol. Med.</i> , 34:1078-1088, 2003.
	C277	Scriver <i>et al.</i> , In: The metabolic and molecular bases of inherited disease. 7 th ed., NY, McGraw-Hill, 1995.
	C278	Sehba <i>et al.</i> , "Effects of S-Nitrosoglutathione on Acute Vasoconstriction and Glutamate Release After Subarachnoid Hemorrhage," <i>Stroke</i> , 30:1955-1961, 1999.
	C279	Sehba <i>et al.</i> , "Treatment with nitric oxide donor decreases ischemic glutamate release after subarachnoid hemorrhage," <i>Society for Neuroscience Abstracts</i> , 1998 (Abstract 102.6).
	C280	Sekhon <i>et al.</i> , "N-Acetyl cysteine protects against injury in a rat model of focal cerebral ischemia," <i>Brain Res.</i> , 971:1-8, 2003.
	C281	Sekhon <i>et al.</i> , "N-acetyl cysteine protects against injury in animal model of transient focal cerebral ischemia," <i>J. Neurochem.</i> , 81:103, 2002 (Abstract No. CP11-12).
	C282	Sequeira <i>et al.</i> , "Modulation of glutamate release from rat hippocampal synaptosomes by nitric oxide," <i>Nitric Oxide</i> , 1:315-329, 1997.
	C283	Sherman <i>et al.</i> , "Pyrrolidine dithiocarbamate inhibits induction of nitric oxide synthase activity in rat alveolar macrophages," <i>Biochemical and Biophysical Research Communications</i> , 191:1301-1308, 1993.
	C284	Simmons and Murphy, "Induction of nitric oxide synthase in glial cells," <i>J. Neurochem.</i> , 59:897-905, 1992.
	C285	Sinensky <i>et al.</i> , "Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis," <i>J. Biol. Chem.</i> , 265:19937-19941, 1990.
	C286	Singh <i>et al.</i> , "Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases," <i>J. Biol. Chem.</i> , 273:20354-20362, 1998.
/MA/	C287	Singh, "Biochemistry of peroxisomes in health and disease," <i>Mol. Cell Biochem.</i> , 167:1-29, 1997.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C288	Smith <i>et al.</i> , "Demyelination: the role of reactive oxygen and nitrogen species," <i>Brain Pathol.</i> , 9:69-92, 1999.
	C289	Sochman <i>et al.</i> , "Infarct size limitation: acute N-acetylcysteine defense (ISLAND trial): preliminary analysis and report after the first 30 patients," <i>Clin Cardiol.</i> , 19:94-100, 1996.
	C290	Sparks, "Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease?" <i>Ann. N.Y. Acad. Sci.</i> , 826:128-146, 1997.
	C291	Spiegel and Merrill, "Sphingolipid metabolism and cell growth regulation," <i>Faseb. J.</i> , 10:1388-1397, 1996.
	C292	Spiegel and Milstien, "Sphingosine-1-phosphate: signaling inside and out," <i>FEBS Lett.</i> , 476:55-57, 2000.
	C293	Sprenkle <i>et al.</i> , "Identification of Raf-1 Ser621 kinase activity from NIH 3T3 cells as AMP-activated protein kinase," <i>FEBS Lett.</i> , 403:254-258, 1997.
	C294	Stadler <i>et al.</i> , "Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide," <i>J. Immunol.</i> , 147:3915-3920, 1991.
	C295	Stamler <i>et al.</i> , "(S)NO Signals: Translocation, Regulation, and a Consensus Motif," <i>Neuron</i> , 18:691-696, 1997.
	C296	Stanislaus <i>et al.</i> , "Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis," <i>J. Neurosci. Res.</i> , 66:155-162, 2001.
	C297	Stefanelli <i>et al.</i> , "Inhibition of glucocorticoid-induced apoptosis with 5-aminoimidazole-4-carboxamide ribonucleoside, a cell-permeable activator of AMP-activated protein kinase," <i>Biochem. Biophys. Res Commun.</i> , 243:821-826, 1998.
	C298	Steffen <i>et al.</i> , "Metabolism of S-nitrosoglutathione in intact mitochondria," <i>Biochem. J.</i> , 356:395-402, 2001.
	C299	Stein <i>et al.</i> , "The regulation of AMP-activated protein kinase by phosphorylation," <i>Biochem. J.</i> , 345:437-443, 2000.
	C300	Stevens <i>et al.</i> , "The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice," <i>Brain Res.</i> , 932:110-119, 2002.
/MA/	C301	Stewart and Heales, "Nitric oxide-induced mitochondrial dysfunction: implications for neurodegeneration," <i>Free Radic. Biol. Med.</i> , 34:287-303, 2003.

25725722.1

EXAMINER: /Maury Audet/


DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C302	Stoll <i>et al.</i> , "Inflammation and glial responses in ischemic brain lesions," <i>Prog. Neurobiol.</i> , 56:149-171, 1998.
	C303	Stüve <i>et al.</i> , "The potential therapeutic role of statins in central nervous systems autoimmune disorders," <i>Cell. Mol. Life Sci.</i> , 60:2483-2491, 2003.
	C304	Su <i>et al.</i> , "Galanin down-regulates microglial tumor necrosis factor-alpha production by a post-transcriptional mechanism," <i>J. Neuroimmunol.</i> , 134:52-60, 2003.
	C305	Sugimoto and Iadecola, "Effects of aminoguanidine on cerebral ischemia in mice: comparison between mice with and without inducible nitric oxide synthase gene," <i>Neurosci. Lett.</i> , 331:25-28, 2002.
	C306	Sullivan <i>et al.</i> , "Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase," <i>FEBS Lett.</i> , 353:33-36, 1994.
	C307	Suzuki <i>et al.</i> , "Beneficial effects of nitric oxide synthase inhibition on the recovery of neurological function after spinal cord injury in rats," <i>Naunyn Schmiedebergs Arch. Pharmacol.</i> , 363:94-100, 2001.
	C308	Suzuki <i>et al.</i> , "Concurrent formation of peroxynitrite with the expression of inducible nitric oxide synthase in the brain during middle cerebral artery occlusion and reperfusion in rats," <i>Brain Res.</i> , 951:113-120, 2002.
	C309	Taupin <i>et al.</i> , "Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system," <i>Eur. J. Immunol.</i> , 27:905-913, 1997.
	C310	Taylor <i>et al.</i> , "Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene," <i>J. Biol. Chem.</i> , 273:15148-15156, 1998.
	C311	Terkeltaub <i>et al.</i> , "Role of the mevalonate pathway of isoprenoid synthesis IL-8 generation by activated monocytic cells," <i>J. Leukoc. Biol.</i> , 55(6):749-755, 1994.
	C312	The Editors, "Statins & Alzheimer's," <i>HealthNews</i> , 6:1, 2000.
	C313	Thibault, "Phase 1 study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer," <i>Clinical Cancer Research</i> , 2:483-491, 1996.
/MA/	C314	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease," <i>Science</i> , 267:1456-1462, 1995.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C315	Toledano and Patridge, "Statins: not just for cholesterol?" <i>TEM</i> Vol. 11:255-256, 2000.
	C316	Torreilles <i>et al.</i> , "Neurodegenerative disorders: the role of peroxynitrite," <i>Brain Res. Revs.</i> , 30:153-163, 1999.
	C317	Trifiletti, "Neuroprotective effects of NG-nitro-L-arginine in focal stroke in the 7-day old rat," <i>Eur. J. Pharmacol.</i> , 218:197-198, 1992.
	C318	Tschape <i>et al.</i> , "The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and Appl processing," <i>EMBO J.</i> , 21:6367-6376, 2002.
	C319	Tseng <i>et al.</i> , "Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation," <i>J. Pharmacol. Exp. Ther.</i> , 292:737-742, 2000.
	C320	Tsukada <i>et al.</i> , "Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis," <i>J. Neurol. Sci.</i> , 104:230-234, 1991.
	C321	Turnley <i>et al.</i> , "Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system," <i>J. Neurochem.</i> , 72:1707-1716, 1999.
	C322	van der Veen <i>et al.</i> , "Extensive peroxynitrite activity during progressive stages of central nervous system inflammation," <i>J. Neuroimmunol.</i> , 77:1-7, 1997.
	C323	Van Doornum <i>et al.</i> , "Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis," <i>Ann. Rheum. Dis.</i> , 63:1571-1575, 2004.
	C324	Vaughan and Delanty, "Neuroprotective properties of statins in cerebral ischemia and stroke," <i>Stroke</i> , 30:1969-1973, 1999.
	C325	Vaughan <i>et al.</i> , "Statins do more than just lower cholesterol," <i>The Lancet</i> , 348:1079-1082, 1996.
	C326	Villarroya <i>et al.</i> , "Myelin-induced experimental allergic encephalomyelitis in Lewis rats: tumor necrosis factor alpha levels in serum and cerebrospinal fluid immunohistochemical expression in glial cells and macrophages of optic nerve and spinal cord," <i>J. Neuroimmunol.</i> , 64:55-61, 1996.
	C327	Vincent <i>et al.</i> , "Inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside in isolated rat hepatocytes," <i>Diabetes</i> , 40:1259-1266, 1991.
/MA/	C328	Viollet <i>et al.</i> , "The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity," <i>J. Clin. Invest.</i> , 111:91, 2003.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C329	Virag <i>et al.</i> , "Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention," <i>Toxicol. Lett.</i> , 140-141:113-124, 2003.
	C330	Vodovotz <i>et al.</i> , "Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease," <i>J. Exp. Med.</i> , 184:1425-1433, 1996.
	C331	Vodovotz <i>et al.</i> , "S-nitrosoglutathione reduces nonocclusive thrombosis rate following balloon overstretch injury and intracoronary irradiation of porcine coronary arteries," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> , 48:1167-1174, 2000.
	C332	Wada <i>et al.</i> , "Inducible Nitric Oxide Synthase Expression after Traumatic Brain Injury and Neuroprotection with Aminoguanidine Treatment in Rats," <i>Neurosurgery</i> , 43:1427-1436, 1998.
	C333	Wada <i>et al.</i> , "Role of nitric oxide in traumatic brain injury in the rat" <i>J. Neurosurg.</i> , 89:807-818, 1998.
	C334	Waldmeier, "Prospects for antiapoptotic drug therapy of neurodegenerative diseases," <i>Prog. Neuropsychopharmacol. Biol. Psychiatry</i> , 27:303-321, 2003.
	C335	Weigand <i>et al.</i> , "N-acetylcysteine attenuates the increase in α -glutathione S-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in humans undergoing liver transplantation," <i>Transplantation</i> , 72(4):694-698, 2001.
	C336	Welsh <i>et al.</i> , "Interleukin-1beta-Induced Nitric Oxide Production in Isolated Rat Pancreatic Islets Requires Gene Transcription and May Lead to Inhibition of the Krebs Cycle Enzyme Aconitase," <i>Endocrinol.</i> , 129:3167-3173, 1991.
	C337	White <i>et al.</i> , "Superoxide and peroxynitrite in atherosclerosis," <i>Proc. Natl. Acad. Sci. USA</i> , 91:1044-1048, 1994.
	C338	Wiesner and Dawson, "Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway," <i>J. Neurochem.</i> , 66:1418-1425, 1996.
	C339	Willmot and Bath, "The potential of nitric oxide therapeutics in stroke," <i>Expert Opin. Investig. Drugs</i> , 12:455-470, 2003.
	C340	Winder and Hardie, "AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes," <i>Am. J. Physiol.</i> , 277:E1-E10, 1999.
/MA/	C341	Winlaw <i>et al.</i> , "Increased nitric oxide production in heart failure," <i>Lancet</i> , 344:373-374, 1994.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)	Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Inderjit Singh	
	Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C342	Wolozin <i>et al.</i> , "Decreased prevalence of alzheimer disease associated with 3-Hydroxy-3-Methylglutaryl Coenzyme A reductase inhibitors," <i>Arch. Neurol.</i> , 57:1439-1443, 2000.
	C343	Won <i>et al.</i> , "Stimulation of astrocyte-enriched culture with C2 ceramide increases proenkephalin mRNA: involvement of cAMP-response element binding protein and mitogen activated protein kinases," <i>Brain Res.</i> , 903:207-215, 2001.
	C344	Wu <i>et al.</i> , "Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat," <i>Br. J. Pharmacol.</i> , 114:1273-1281, 1995.
	C345	Xi and Zhang, "Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase," <i>J. Biol. Chem.</i> , 276:41029-41034, 2001.
	C346	Xie <i>et al.</i> , "Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase," <i>J. Biol. Chem.</i> , 269:4705-4708, 1994.
	C347	Yang <i>et al.</i> , "Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors," <i>J. Biol. Chem.</i> , 276:38341-38344, 2001.
	C348	Yao <i>et al.</i> , "DNA fragmentation in ischemic core and penumbra in focal cerebral ischemia in rats," <i>Brain Res. Mol. Brain Res.</i> , 91:112-118, 2001.
	C349	Yeh <i>et al.</i> , "Lactosylceramide mediates shear-induced endothelial superoxide production and intercellular adhesion molecule-1 expression," <i>J. Vasc. Res.</i> , 38:551-559, 2001.
	C350	Young, "Secondary injury mechanisms in acute spinal cord injury," <i>J. Emerg. Med.</i> , 11:13-22, 1993.
	C351	Zagariya <i>et al.</i> , "Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun," <i>Mol. Cell Biol.</i> , 18:2815-2824, 1998.
	C352	Zamrini <i>et al.</i> , "Association between statin use and Alzheimer's disease," <i>Neuroepidemiology</i> , 23:94-98, 2004.
↓	C353	Zembowicz and Vane, "Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line," <i>Proc. Natl. Acad. Sci. USA</i> , 89:2051-2055, 1992.
/MA/	C354	Zeng <i>et al.</i> , "Metabolism of S-nitrosoglutathione by endothelial cells," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 281:H432-439, 2001.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Form PTO-1449 (modified)		Atty. Docket No. MESC:013US	Serial No. 10/596,198
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Inderjit Singh	
		Filing Date: June 2, 2006	Group: 2622
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-29</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/MA/	C355	Zhang <i>et al.</i> , "Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients," <i>Diabetes Res. Clin. Practice</i> , 29:189-194, 1995.
↓	C356	Zhang <i>et al.</i> , "Molecular cloning and analysis of the rat inducible nitric oxide synthase gene promoter in aortic smooth muscle cells," <i>Biochem. Pharmacol.</i> , 55:1873-1880, 1998.
↓	C357	Zhang <i>et al.</i> , "Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity," <i>Science</i> , 263:687-689, 1994.
↓	C358	Zhang <i>et al.</i> , "Nitric oxide donors increase blood flow and reduce brain damage in focal ischemia: evidence that nitric oxide is beneficial in the early stages of cerebral ischemia," <i>J. Cereb. Blood Flow Metab.</i> , 14:217-226, 1994.
↓	C359	Zhao <i>et al.</i> , "Gene-dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase," <i>Brain Res.</i> , 872:215-218, 2000.
↓	C360	Zhao <i>et al.</i> , "L-Arginine increases ischemic injury in wild-type mice but not in iNOS-deficient mice," <i>Brain Res.</i> , 966:308-311, 2003.
↓	C361	Zhu <i>et al.</i> , "Inducible nitric oxide synthase expression in the ischemic core and penumbra after transient focal cerebral ischemia in mice," <i>Life Sci.</i> , 71:1985-1996, 2002.
/MA/	C362	Zielasek <i>et al.</i> , "Production of nitrite by neonatal rat microglial cells/brain macrophages," <i>Cell Immunol.</i> , 141:111-120, 1992.

25725722.1

EXAMINER: /Maury Audet/

DATE CONSIDERED: 01/04/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/